

BAB 5

KESIMPULAN DAN SARAN

5.1 Kesimpulan

Berdasarkan hasil penelitian yang berjudul Studi Penggunaan Natrium Valproat Lebih Dari Tiga Bulan Terhadap Magnesium Serum dan Jumlah Kejang Pasien Epilepsi Di RSUD Dr. Soetomo periode Juli 2017 sampai September 2017 diperoleh kesimpulan sebagai berikut :

1. Tidak terdapat peningkatan kadar serum Mg^{2+} pada pasien epilepsi yang memperoleh terapi obat natrium valproat selama lebih dari 3 bulan.
2. Tidak terdapat peningkatan kadar serum Mg^{2+} dengan terapi natrium valproat pada pasien epilepsi dengan masa perawatan terapi lebih dari 3 bulan dengan jumlah kejangnya.
3. Tidak terdapat *Drug Related Problem* dalam penelitian ini.

5.2 Saran

1. Sebaiknya dilakukan terlebih dahulu pemantauan *pre* dan *post* kadar magnesium terhadap penggunaan terapi natrium valproat kemudian hasil tersebut dapat dibandingkan. Dengan demikian, diharapkan dapat memberikan gambaran yang jelas mengenai pengaruh dari magnesium terhadap kejang sebelum dan setelah mendapatkan terapi.
2. Perlu dilakukan perluasan rentang usia, karena penderita epilepsi juga lebih banyak terjadi pada anak – anak, sehingga diharapkan jumlah sampel lebih banyak lagi.
3. Tempat penelitian dapat diperluas lagi tidak hanya di ruang tindakan EEG namun dapat juga dilakukan di instalasi rawat jalan. Sehingga jumlah sampel lebih banyak dan dapat memenuhi target.

DAFTAR PUSTAKA

- Adams, R. D., Victor, M. 1993, *The Nature of the Discharging Lesion, in: Principles of Neurology*, 5th edition, McGraw-Hill, New York, 284-286.
- AHFS. 2011, *AHFS Drug Information*, American Society of Health System Pharmacists, Bethesda.
- Ahsan, S. K., Al-swoyan, S., Hanif, M. 1998, Hypomagnesemia and clinical implications in children and neonates. *Indian J Med Sei.* **52(12)**:541-547
- Aldenkamp AP. 2006. Cognitive Impairment in Epilepsy: *State of Affairs and Clinical Relevance Seizure.* **15** : 219-220.
- Altura, Burton, M., Gebrewold, A., Zhang, A, Altura, Bella, T, 2003, 'Low extracellular magnesium ions induce lipid peroxidation and activation of nuclear factor-kappa B in canine cerebral vascular smooth muscle: possible relation to traumatic brain injury and strokes', *Neuroscience Letters*, **341** : 189-192.
- Amrita, S., Kamalesh, D., Nilay, K.D, Dibyendu, C., Goutameswar, M. and Santanu, K.T. 2012, Use of anti-epileptic drugs in a tertiary care hospital of Eastern India with emphasis on epilepsy due to neurocysticercosis, *Indian J Pharmacol*, **44(1)**: 106-110.
- Ariza, A.C., Bobadilla, N., Fernandez, C., Munoz-Fuentes, R.M., Larrea, F. and Halhali, A., 2005. Effects of magnesium sulfate on lipid peroxidation and blood pressure regulators in preeclampsia, *Clin. Biochem.* **38** : 128-133.
- Asdie, A. H. 2000, *Prinsip-prinsip Ilmu Penyakit Dalam*, Vol. 5, Edisi 13, Penerbit Buku Kedokteran EGC, Jakarta, 2453-2463.
- Baggot, P.J., Kalamarides, J.A. and Shoemaker, J.D. 1999, Valproate-induced biochemical abnormalities in pregnancy corrected by vitamins: a case report. *Epilepsia*, **40**: 512-515.
- Barbosa, F.J., Hesse, B., Almeida R.B., Baretta I.P., Boerngen L, Roseli., Andreatini, R. 2011, Magnesium sulfate and sodium valproate block methylphenidate-induced hyperlocomotion, an animal model of mania, *Pharmacological report*, **63 (1)**: 64-70.
- Brodie MJ, Schachter SC. 2001, *Fast fact epilepsy*. 2nd ed. Oxford : Health Press Ltd, 62 – 65.

- Bussiere, FI., Gueux, E., Rock, E., Mazur, A. and Rayssiguier, Y. 2002, Protective effect of calcium deficiency on the inflammatory response in magnesium-deficient rats, *Eur. J. Nutr.*, **41**: 197-202.
- Cao, H.Y., Jiang, Y.W., Liu, Z.W. 2003, Effect of recurrent epileptiform discharges induced by magnesium-free treatment on developing cortical neurons in vitro, *Journal Brain Research. Developmental Brain Research*, **142**: 1-6.
- Chauhan, U.P., Sarkar, B.C. 1969, Use of calmagite for the determination of traces of magnesium in biological materials, *Analytical Biochemistry*, **32**: 70-80
- Chernow, B, Bamberger, S, Stoiko, M, 1989, Hypomagnesemia in patients in postoperative intensive care", *Chest* : **95(2)**, 391-397.
- Clarke R, Smith A D, Jobst K A, Refsum H, Sutton L, Ueland PM. 1998. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. *Journal Archives of neurology*, **55**: 1449-55
- Cotario, D., Evans, S., Zaidman, J.L. and Marcus, O. 1990, Early changes in hepatic redox homeostasis following treatment with a single dose of valproic acid. *Biochemical Pharmacology*, **40**: 589-593.
- Cotton, D.B., Hallak, M., Janusz, C. 1993, Central anticonvulsant effects of magnesium sulfate on N-Methyl-D-aspartate-induced-seizures. *Department of Obstetrics and Gynecology*, **168(3)** : 974-978.
- Elaine, W., Gregory, D., Cascino, Barry E. Gidal, Howard P. Goodkin-Wyllie's, 2010. *Treatment of Epilepsy Principles and Practice* (Wyllie, *Treatment of Epilepsy*), Philadelphia, USA; Lippincott Williams & Wilkins.
- Eussen S.J, De Groot L.C, Joosten L.W, Bloo R.J, Clarke R, Ueland P.M. 2006. Effect of oral vitamin B-12 with or without folic acid on cognitive function in older people with mild vitamin B-12 deficiency: a randomized, placebo controlled trial. *The American Journal of Clinical Nutrition*; **84**:361-370.
- Fawcett, W.J., Haxby, E.J., Male, D.A. 1999, Magnesium: physiology and pharmacology, *British Journal of Anaesthesia*. **83(2)** : 302—320.
- Fosgren L. 2001. Epidemiology of epilepsy: a global problem. Program and abstracts of the 17th World Congress of Neurology. *Journal Neurology Science*. **187(1)**: 212

- Fueta, Y., Siniscalchi, A., Tancredi, V., Avoli, M. 1995, Extracellular magnesium and anticonvulsant effects of valproate in young rat hippocampus, *Epilepsia*, **36** : 404–409.
- Gandaiah, P, Venkateshwarlu, N, Ramakrishna, S, dkk. 2014, „Role of Magnesium in Convulsive Disorders”, *Indian Journal of Public Health Research & Development*, **5(1)** : 60 – 63.
- Gathwala, G. 2001, Neuronal protection with magnesium, *The Indian Journal of Pediatrics*, **68** : 417 - 419.
- Harsono. 2009, *Buku Ajar Neurologi Klinis*, Gadjah Mada University Press, Yogyakarta.
- Heinz, L., Lutz, H.M.D., Klaus, M.M.D., Detlef, B.M.D., M.D, 2005. *Color Atlas of Pharmacology*, 3rd Edition, Thieme Stuttgart, New York.
- Husam., Kustiowati, Endang, 2008, Perbedaan Usia Dan Jenis Kelamin Pada Jenis Epilepsi Di RSUP Dr. Kariadi, *Skripsi*, Sarjana Kedokteran, Universitas Diponegoro Fakultas Kedokteran, Semarang
- Ilhan, A., Aladag, M.A., Kocer, A., Boluk, A., Gurel, A. and Armutcu, F. 2005, Erdosteine ameliorates PTZ-induced oxidative stress in mice seizure model, *Brain Research Bulletin*, **65**: 495–499.
- Ilhan, A., Iraz, M., Kamisli, S., Yigitoglu, R. 2006. Pentylentetrazol-induced kindling seizure attenuated by *Ginkgo biloba* extract (EGb 761) in mice, *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, **30**, 1504–1510.
- Kang S.S, Wong P.W, Malinow M.R. 1992, Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. *Journals NCBI : Annual Review of Nutrition*, **12** :279-98
- Katzung G. Bertram., MD, PhD, 2007; *Basic & Clinical Pharmacology* - 10th Edition ; McGraw-Hill Medical.
- Kuzniar, A., Mitura, P., Kurys, P., Szymonik-Lesiuk, S., Florianczyk, B. and Stryjecka-Zimmer, M. 2003, The influence of hypomagnesemia on erythrocyte antioxidant enzyme defence system in mice, *Biometals*, **16**: 349–357.
- La Rue A, Koehler K, M, Wayne J, S, Chiulli J,S, Haaland K,Y, Garry PJ. 2000. Nutritional status and cognitive functioning in a normally

- aging sample: a 6-y reassessment. *The American Journal of Clinical Nutrition*; **65**:20-9.
- Lacy, Charles F., 2009, *Drug Information Handbook*, American Pharmacists Association.
- Laurence, B., Bruce, C., Bjorn Knollman-Goodman and Gilman. 2011, *The Pharmacological Basis of Therapeutics* ; McGraw-Hill Education Medical. Section II, Chapter 21, 583
- Loscher, W. 1993, In vivo administration of valproate reduces the nerve terminal (synaptosomal) activity of GABA aminotransferase in discrete brain areas of rats, *Neuroscience Letters*, **160**, 177–180.
- Mark, C., Samden, L. 2013, *Oxford Textbooks in Clinical Neurology;Oxford Textbook of Epilepsy and Epileptic Seizures*, Oxford University Press, 245-247
- Kamienski, Mary., Keogh, Jim, 2006. *Pharmacology Demystified*, McGRAW-HILL, 317.
- Michael, N.J. 2015, *Medical Pharmacology at a Glance*, Wiley Blackwell, 50-51.
- Moetazza A. M., Seham S. K and Madeha M.A. 2013, Effect of Long Term Treatment with Antiepileptic Drugs on Oxidant Status, Zinc and Magnesium in Epileptic Patients, *World Applied Sciences Journal*, **28 (3)**: 316-323.
- Octaviana, F. 2008, *Epilepsi: Permasalahan di Reseptor atau Neurotransmitter*, *Medicinus Scientific Journal of Pharmaceutical Development and Medical Application*, **21(4)**: 121-124.
- Ortinski P, Meador K.J. 2004. Cognitive side-effects of antiepileptic drugs. *Epilepsy Behav.* **5**: 60-65.
- Osborn, E., Katie., Shytle, D R., Frontera Alfred T., Soble,J R., and Schoenberg Mike R., 2016, Addressing Potential Role Of Magnesium Dyshomeostatis To Improve Treatment Efficacy For Epilepsy: A Reexamination Of The Literature. *The Journal of Clinical Pharmacology*, **56**: 260–265
- Patsoukis, N., Zervoudakis, G., Georgiou, C.D., Angelatou, F., Matsokis, N.A. and Panagopoulos, N.T. 2004, Effect of pentylenetetrazol-induced epileptic seizure on thiol redox state in the mouse cerebral cortex, *Epilepsy Res*, **62** : 65–74.

- PERDOSSI. 2008. *Pedoman Tatalaksana Epilepsi*. Edisi ke 3. Jakarta, hal 29
- Pinzon, R, 2006, Karakteristik Epidemiologi Onset Anak-Anak. *Dexa Media*, **19(3)** : 131 – 133.
- Rogawski, M.A., Loscher, W. 2004, The neurobiology of antiepileptic drugs, *Nature Reviews Neuroscience*, **5**: 553–564.
- Rude, R.K. 1998, Magnesium deficiency : a cause of heterogenous disease in humans, *Journal of Bone and Mineral Research*. **13(4)**:749-58.
- Safar, M.M., Dallal, M.A., Arafa, M.N., Abdel A.T.M, 2010, Magnesium supplementation enhances the anticonvulsant potential of valproate in pentylenetetrazol-treated rats, *Brain Research*, **1334** : 58-64.
- Sharma, P., Chung, C., Vizcaychipi, M. 2014, Magnesium: The neglected electrolyte? A clinical review, *Pharmacology & Pharmacy*. **5** : 762-772.
- Shorvon S. 2001. Status epilepticus. Program and abstracts of the 17th World Congress of Neurology. *J Neurol Sci.* , **187(1)**: 213.
- Sudha, K., Rao, A.V., Rao, A., 2001. Oxidative stress and antioxidants in epilepsy. *Clinica Chimica Acta*, **303**: 19–24.
- Suwarba, I.G.N.M. 2011, *Insiden dan Karakteristik Klinis Epilepsi pada Anak*, *Sari Pediatri*, **13(2)** : 123-128.
- Trinka, Eugene. 2007. The use of valproate and new antiepileptic drugs in status epilepticus, *Epilepsia*, **48(8)** : 49–51.
- Turkoglu, O.F., Eroglu, H., Okutan, O., Tun, M.K., Bodur, E., Sargon, M.F., Oner, L. and Beskonakli, E. 2008, A comparative study of treatment for brain edema: magnesium sulphate versus dexamethasone sodiumphosphate, *Journal of Clinical Neuroscience - Elsevier*, **15** : 60–65.
- Wahyono, D. 2013, *Farmakokinetika Klinik Konsep Dasar dan Terapan dalam Farmasi Klinik*, Gadjah Mada University Press, Yogyakarta, 3-21.
- Wells G. Barbara, DiPiro T Joseph, Schwinghammer L Terry, DiPiro V. Cecily, 2015. *Pharmacotherapy Handbook Ninth Edition*, McGraw-Hill, 518-542.

- WHO. 2001. Epilepsy: aetiology, epidemiology and prognosis. Diakses pada Februari 2001 <http://www.who.int/factsheets/fs165/en/print.html>.
- William, B., Barr., Chris, M. 2015, *Clinical Handbooks in Neuropsychology ; Handbook on the Neuropsychology of Epilepsy*, Springer, Verlag New York. 1: 6-10
- Winter, H.G. 1994, *Buku Pintar Kesehatan, 796 Gejala, 520 Penyakit, 160 Pengobatan*, Penerbit Arcan, Jakarta.
- Yasiry, Z., Shorvon, S.D. 2014. The relative effectiveness of five antiepileptic drugs in treatment of benzodiazepine-resistant convulsive status epilepticus: A meta-analysis of published studies. *Seizure*, **23**: 167–174.
- Yuen, W.C., Alan., Josemir, W., Sandera. 2012, Can magnesium supplementation reduce seizures in people with epilepsy? A hypothesis, *Epilepsy Research*, **100** : 152—156.